newsfilter
← Latest News
Business Wire·

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

OGN
  • Organon presented pooled Phase 3 ADORING 1 & 2 trial data at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, MN, breaking out results by pediatric and adult age subsets for the first time.
  • VTAMA cream (tapinarof) is the first & only aryl hydrocarbon receptor (AhR) agonist indicated for atopic dermatitis in patients aged 2 years & older & plaque psoriasis in adults.
  • The post hoc analysis of 813 patients showed consistent improvements in skin clearance (vIGA-AD response) & EASI75 across age groups 2–6, 7–11, 12–17, & 18+ years by week 8.
  • Therapeutic responses were observed as early as week 2 & continued through the 8-week treatment period for all pediatric & adult age groups.
  • Week 8 vIGA-AD response rates for VTAMA cream vs. vehicle were: 56.3% vs. 11.8% (ages 2–6), 44.9% vs. 23.8% (ages 7–11), 48.8% vs. 13.4% (ages 12–17), & 38.0% vs. 18.1% (adults).
  • Week 8 EASI75 response rates for VTAMA cream vs. vehicle were: 70.2% vs. 20.5% (ages 2–6), 53.6% vs. 31.3% (ages 7–11), 62.2% vs. 18.3% (ages 12–17), & 50.8% vs. 20.6% (adults).
  • Most treatment-emergent adverse events were folliculitis, headache, & nasopharyngitis, generally mild to moderate, with fewer discontinuations due to adverse events for VTAMA cream than vehicle.
  • VTAMA cream is a steroid-free, topical AhR agonist recommended by the American Academy of Dermatology for pediatric & adult atopic dermatitis.
  • The ADORING program includes two 8-week pivotal trials (ADORING 1 & 2) & a 48-week open-label extension trial (ADORING 3).
  • Atopic dermatitis affects up to 20% of children worldwide & approximately 26 million people in the U.S.